Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction should not be conflated with “FDA”-approved prescription fentanyl therapies such as transdermal fentanyl patches, which it said are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients. The White House+1 The company noted ongoing concerns around transdermal fentanyl patch abuse and accidental pediatric exposure and said it is partnering with Kindeva to develop AVERSA(TM) FENTANYL, which combines Nutriband AVERSA(TM) abuse-deterrent technology with Kindeva FDA-approved fentanyl patch to deter abuse and reduce accidental exposure while maintaining access for patients who need prescription fentanyl products. Nutriband said AVERSA(TM) FENTANYL could be the first abuse-deterrent opioid patch and has the potential to reach peak annual U.S. sales of $80 million to $200 million, with an initial focus on the U.S. market and a stated goal of broader availability in major global medical markets.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer